Seattle, biotechnology startup HDT Bio raises $3M to support development of COVID-19 vaccine

| < 1 minute read

Seattle-based biotech company HDT Bio enabling global access to immunotherapies for oncology and infectious disease, closed its seed financing round, totalling ~$3M.

HDT-301 is a cutting-edge, replicating RNA vaccine. In this approach to preventing illness, the vaccine contains a string of RNA from the virus, which cells turn into protein, triggering an immune response. In traditional vaccines, the targeted virus or pathogen is inactivated and then injected into the body.

The vaccine includes an ingredient called a Lipid InOrganic Nanoparticle, or LION, which improves its stability, delivery, and immune response. LION was developed by HDT Bio. Researchers are excited about the RNA vaccine strategy because it’s quick to develop and elicits a strong immune response. The approach, however, has never been cleared for use in humans.

According to Chief Operating Officer Christopher Pirie, the company is hoping to start a clinical trial of the vaccine in human volunteers in Brazil this month. Trials in the U.S. and India could launch in November.

The world’s scientists are developing a vaccine, and currently, it is in a clinical trial phase, no country has developed a COVID-19 vaccine successfully as per WHO. As per sources, we can expect the first vaccine by the end of 2020.


Posted in

About the author

Related Posts

Startup Of The Week – NutSpace

Everything we do, we do to brighten the future of our children by making them creative, innovative and better human beings. We shape the future of our children by using simple theme-based stories that are easy to understand, encourage reflection, impart knowledge and drive curiosity. We design story-based courses for children, parents and teachers. Currently, we are focusing on creating content for children (and their parents/teachers) of 0-8 years.